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Abstract
Background: The finding of human umbilical cord blood as one of the most likely sources of hematopoietic stem
cells offers a less invasive alternative for the need of hematopoietic stem cell transplantation. Due to the once-in-a-
life time chance of collecting it, an optimum cryopreservation method that can preserve the life and function of
the cells contained is critically needed.
Methods: Until now, slow-cooling has been the routine method of cryopreservation; however, rapid-cooling offers
a simple, efficient, and harmless method for preserving the life and function of the desired cells. Therefore, this
study was conducted to compare the effectiveness of slow- and rapid-cooling to preserve umbilical cord blood of
mononucleated cells suspected of containing hematopoietic stem cells. The parameters used in this study were
differences in cell viability, malondialdehyde content, and apoptosis level. The identification of hematopoietic stem
cells themselves was carried out by enumerating CD34
+ in a flow cytometer.
Results: Our results showed that mononucleated cell viability after rapid-cooling (91.9%) was significantly higher
than that after slow-cooling (75.5%), with a p value = 0.003. Interestingly, the malondialdehyde level in the
mononucleated cell population after rapid-cooling (56.45 μM) was also significantly higher than that after slow-
cooling (33.25 μM), with a p value < 0.001. The apoptosis level in rapid-cooling population (5.18%) was not
significantly different from that of the mononucleated cell population that underwent slow-cooling (3.81%), with a
p value = 0.138. However, CD34
+ enumeration was much higher in the population that underwent slow-cooling
(23.32 cell/μl) than in the one that underwent rapid-cooling (2.47 cell/μl), with a p value = 0.001.
Conclusions: Rapid-cooling is a potential cryopreservation method to be used to preserve the umbilical cord
blood of mononucleated cells, although further optimization of the number of CD34
+ cells after rapid-cooling is
critically needed.
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The success of the first human umbilical cord blood
transplantation in 1988 has opened a new perspective
on the use of human umbilical cord blood, which is
usually discarded after the delivery process. Further
research about the properties of human umbilical cord
blood led to reports that there are some types of stem
cells in umbilical cord blood mononucleated cells,
including hematopoietic stem cells. Equal to any other
type of stem cells, hematopoietic stem cells have some
unique characteristics, such as the ability to self-renew
and differentiate into every type of cell in hematopoietic
lineages. Until now, at least three sources are known for
their potential to become the source of hematopoietic
stem cells, i.e., the bone marrow, umbilical cord, and
peripheral blood. Of the three, bone marrow is the most
commonly used source of hematopoietic stem cells for
transplantation. Although it has been proven to be quite
effective, the collection of hematopoietic stem cells from
bone marrow is an invasive and traumatic procedure.
On the other hand, the use of peripheral blood requires
a preliminary procedure, such as the administration of
the granulocyte colony stimulating factor (G-CSF) prior
to collection.
Research by Broxmeyer et al. showed that umbilical
cord blood is rich in adult stem cells, including hemato-
poietic stem cells [1]. Because the procedure is less inva-
sive and not traumatic, umbilical cord blood offers a
safer and more effective procedure for patients in need
of hematopoietic stem cell transplantation. It has also
been proven that hematopoietic stem cells obtained
from umbilical cord blood have less imunological prop-
erties than hematopoietic stem cell obtained from umbi-
lical cord blood have fewer immunological properties
than hematopoietic stem cells obtained from any other
sources; therefore, their use presents a lower risk of
Graft versus Host Disease (GvHD) in allogenic hemato-
poietic stem cell transplantation. The ratio between
hematopoietic stem cells and other mononucleated cells
is also considerably high, ranging from 1: 10
4 to 1: 10
5
cells. Currently, hematopoietic stem cell transplantation
is widely used for non-malignant and malignant hema-
tological diseases [2-4].
Because umbilical cord blood can be obtained only
once in a person’s lifetime, the cryopreservation of
umbilical cord blood mononucleated cells is one of the
most important steps to ensure the future use of hema-
topoietic stem cells. The optimum method of cryopre-
servation should preserve the number and functional
quality of hematopoietic stem cells. Currently, slow-
cooling is the most frequently used method of cryopre-
servation. This method has been widely used to preserve
various types of cells, tissues, and even organs. Since
each type of cell has its own characteristics, researchers
believe that each cell should be preserved according to
its specific characteristics [5]. Several factors known to
contribute to the success rate of cryopreservation are
the freezing and thawing rate and the type and amount
of cryoprotectant used in the medium [6]. Logically,
those factors must be adjusted according to the type of
desired cells or tissues.
Slow-cooling requires gradually declining temperature
with certain freezing rates. The consequences of the
slow and gradual freezing used in the slow-cooling
method have been demonstrated to cause cellular injury,
resulting in cell death, especially in the range of critical
temperatures from -15°C to -60°C. In the context of
freezing and thawing, cells must pass through this criti-
cal range of temperatures twice [7]. Furthermore, the
transition of the preserved cells and surrounding materi-
als from the fluid to the solid state, or vice versa, could
cause osmotic injury, resulting in cell death. Due to the
possible mechanisms that can cause injury and death in
those cells undergoing slow-cooling, rapid-cooling is a
potential alternative solution [8].
Rapid-cooling is a cryopreservation method that
requires an ultra-rapid cooling rate. This procedure is
based on the principle of direct contact between a spe-
cimen dissolved in a cryoprotectant medium and liquid
nitrogen [9]. Because of its rapid-cooling rate and high
viscosity, a specimen that undergoes rapid-cooling is
not expected to have any intracellular and extracellular
ice crystal formation. To achieve the desired level of
viscosity that could turn a fluid into a glassy appear-
ance, a much higher concentration of cryoprotectant
than that used for slow-cooling is usually added to the
rapid-cooling medium. This step has been one of the
most challenging dilemmas because a higher concen-
tration of cryoprotectant would also mean a higher
risk of evoking cellular injuries that might lead to cell
death. Therefore, research on the optimization of the
cooling rates and cryoprotectant concentration should
be conducted prior to the routine use of rapid-cooling
on any cell types [10,11]. So far, rapid-cooling has
been successfully used for the preservation of sperma-
tozoa [11,12], oocytes [13-16], embryos [17-19], and
embryonic stem cells [20,21]. This research was con-
ducted due to the need to optimize the cryopreserva-
tion method for umbilical cord blood and the
weaknesses presented by thes l o w - c o o l i n gm e t h o di n
preserving umbilical cord blood containing hemato-
poietic stem cells. To evaluate the success of cryopre-
servation methods, this study used scientific
parameters, including cell viability, the formation of
malondialdehyde as the product of lipid peroxidation
process, the level of apoptosis based on DNA fragmen-
tation, and the enumeration of CD34
+ as a marker of a
hematopoietic stem cell.
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cocktail for rapid-cooling, in particular, for the preserva-
tion of hematopoietic stem cells contained in umbilical
cord blood, preliminary study was conducted in order to
obtain a concentration that could be more effective than
that used in the optimized slow-cooling method. The
purpose of this study was to scientifically compare the
two cryopreservation methods, slow-cooling and rapid-
cooling, to determine which one should be used routi-
nely for the preservation of umbilical cord blood in
Indonesia.
Methods
Sample Collection
Following approval from the Ethical Committee of
Hasan Sadikin Hospital and having obtained informed
consent from every donor, umbilical cord blood was
retrieved from 13 full-term babies at delivery. Other
inclusion criteria were: the pregnancy must be a single-
ton, the fetus must be alive at birth, the mother must be
less than 35 years old, and the collected umbilical cord
blood must be free of Hepatitis B and HIV infections
(clinically tested HBsAg and HIV antibodies). The exclu-
sion criteria used in this study were: a history of smok-
ing and/or alcohol consumption, chronic illness,
collection of less than 40 ml of umbilical cord blood,
and, lastly, less than 2 × 10
7 cells/ml isolated mononu-
cleated cells.
All umbilical cord blood was collected at the Depart-
ment of Obstetrics and Gynecology of Dr. Hasan Sadi-
kin Hospital, Bandung, Indonesia. First, umbilical cords
were clamped and cut immediately after delivery at the
nearest point towards the newborn. The injection place
was swabbed with 10% povidine iodine or 70% alcohol.
The syringe that had been connected to the blood col-
lection bag was then used to collect umbilical cord
blood from the previously sterilized injection site
[22-24]. The range of blood volume collected using this
procedure was between 60 and 150 mL. Umbilical cord
blood was kept at room temperature. The blood bags
were kept in motion so that the blood would be well
mixed with the anticoagulant.
Isolation of Mononucleated Cells
Mononucleated cells were isolated using Ficoll-Hypaque
(density value, 1.077 g/L) on the basis of the principle of
differences in gradient density. Briefly, the umbilical
cord blood was diluted with phosphate buffer saline
human albumin (PBShA) in a ratio of 1: 1. The formula-
tion was then mixed with Ficoll-Hypaque in a ratio of 2:
1. The mixture was centrifugated, which resulted in
layers of cells. The thin layer up to the level of the ery-
throcytes and Ficoll-Hypaque was then gently removed
and placed in a tube with PBShA.
Cryopreservation of Cells Using the Slow-cooling Method
The mononucleated cell suspension was mixed with
freezing solutions then incubated for 2 min at room
temperature. The mixture was then removed and placed
into a 1.8 mL cryovial. Afterwards, the cryovial was put
into a canister, which was eventually placed inside the
cryo-chamber. The cryo- machine was set at a cooling
rate of 2°C/min until it reached -70°C. The cryo- vial
was finally moved into a liquid nitrogen tank at a tem-
perature of -196°C.
Thawing of Samples that Were Previously Cryopreserved
Using the Slow-cooling Method
The cryovial was taken out of the liquid nitrogen tank
and directly incubated at room temperature for 15 min.
The mononucleated cell suspension was then diluted
with PBShA at a ratio of 1: 1 and centrifugated at a
speed of 300 g for 10 min. The supernatant was then
decanted. The pellets were gently removed to be resus-
pended in 2 ml PBShA. The mixture was centrifugated
at a speed of 300 g for 10 min. The remaining pellets
were then resuspended in PBShA. Afterwards, the sam-
ple was finally ready to be used.
Cryopreservation of Cells Using the Rapid-cooling
The suspension of mononucleated cells was mixed with
a rapid-cooling cocktail at a ratio of 1: 5. The mixture
was incubated at room temperature for 1 min. After-
wards, the mixture was removed and placed into 1.8 mL
cryovial, and the cryovial was then placed into a canis-
ter. The canister was finally placed inside the liquid
nitrogen tank at a temperature of -196°C.
Thawing of the Rapid-cooling Samples
The cryovial was taken out of the liquid nitrogen tank
and immediately warmed in a water bath at 37°C for
one min. After the suspension became liquefied, cryo-
preserved mononucleated cells were then diluted in
PBShA (1: 1). The mixture was then centrifugated at a
speed of 300 g for 10 min. The supernatant was then
decanted, and the pellets were resuspended in PBShA.
The suspension was centrifugated at 300 g for 10 min.
The remaining pellets were suspended in PBShA, and
the sample was ready to use.
Evaluation of Mononucleated Cell Viability
The evaluation of cell viability was conducted using Try-
pan blue 0.4%. Afterwards, the cells were enumerated
using an inverted microscope.
Evaluation of Lipid Peroxidation
The isolated mononuclear cells at a concentration of 20
×1 0
6 cells/mL were assessed post-thawing for malon-
dialdehyde as a marker of lipid peroxidation, using the
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OR, USA) according to the manufacturer’s instructions.
The assay involves a spectrophotometric endpoint at
absorbance of 586 nm.
Evaluation of Apoptosis
The evaluation of apoptosis was carried out with the
Terminal deoxynucleotidyl transferase-mediated dUTP
Nick End Labeling (TUNEL) assay kit (Roche™, Catalog
No: 11684795001) according to the manufacturer’s
instructions. The results were then analyzed using a
flow cytometer (FACSCalibur™).
CD34
+ Cell Enumeration
CD34
+ cell labeling was assessed using Anti-CD34 (8B-
12)-FITC (BD™ 348053). The whole enumeration pro-
cess was conducted using a flow cytometer (FACSCali-
bur™). The analysis of CD34
+ enumeration was done
using ISHAGE guidelines for CD34
+ cell determination
[24].
Statistical Analysis
A normality test using the Saphiro-Wilk test was con-
ducted prior to statistical analysis. To compare the
results on the evaluation of cell viability, lipid peroxida-
tion, apoptosis, and enumeration of CD34
+ cells, we
used the dependent t-test for normally distributed data.
On the other hand, for the abnormally distributed data,
we used the Wilcoxon signed-rank test. All statistical
analyses were conducted using software SPSS
® for Win-
dows
® 13
th version. Differences were considered to have
statistical significance when the p value was ≤ 0.05.
Results
This study was conducted over 10 months from January
through October, 2009. The total number of donors
that were preliminarily evaluated was 23. Based on the
inclusion and exclusion criteria, umbilical cord blood
from 13 donors was evaluated in this study. The resul-
tant data were the means that were first analyzed using
the Saphiro-Wilk test. The results of the evaluation of
cell viability after cryopreservation using the slow-cool-
ing and rapid-cooling methods are presented in Table 1.
As seen in Table 1, the mean value of cell viability after
rapid-cooling was significantly higher than that after
slow-cooling. According to the calculation using the
Wilcoxon signed-rank test, the level of confidence for
these results was 95%, which means that there were sig-
nificant differences in the mean values of cell viability in
the compared sample populations, with a p value =
0.003 (p value ≤0.05). A microscopic image of cell viabi-
lity evaluation using Trypan blue is shown in Figure 1.
The quality of human umbilical cord blood mononu-
cleated cell populations cou l da l s ob ea s s e s s e db yt h e
level of oxidative stress. One of the main markers of the
ongoing oxidative stress is lipid peroxidation. The major
end product of lipid peroxidation is malondialdehyde.
The evaluation of malondialdehyde was based on the
reaction between N-methyl-2-phenylindole (NMPI) and
a malondialdehyde substance. The quantitative value of
the absorbance was achieved with a spectrophotometer
at 586 nm absorbance [25]. The value of the absorbance
from each evaluated sample was then inserted into a
formulation provided in the manufacturer’s instructions.
The variables were defined by the value of the absor-
bance from the used standards. The malondialdehyde
standard curve is shown in Figure 2. Based on Table 2
the value of malondialdehyde in samples that were pre-
viously cryopreserved using the rapid-cooling was higher
than that in samples previously cryopreserved using the
slow-cooling method. According to the calculation using
the dependent t-test, the level of confidence for these
results was 95%, which means that there were significant
differences in the mean values of malondialdehyde
between both sample populations, with a p value <
0.001 (p value ≤0.05). These results mean that there
Table 1 The evaluation results of mononucleated cell
viability on samples that were cryopreserved by using
slow-cooling and rapid-cooling method
Viability Slow-Cooling Rapid-Cooling p value*)
(in percentage %)
Mean (SD) 75.50 (17.53) 91.92 (7.50) 0.003
Median 80.20 94.30
Range 32.70-93.80 77.80-98.93
*: p value was calculated by using Wilcoxon signed-rank test
Figure 1 The viability of mononucleated cells was evaluated
with Trypan blue. The bright round cells (noted by a red arrow)
are viable mononucleated cells, whereas the round blue cells (noted
by a black arrow) are non-viable mononucleated cells (100×
magnification).
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that were previously cryopreserved with the rapid-cool-
ing than in those that were previously cryopreserved
with the slow-cooling method. This could also mean
that the level of oxidative stress was much higher in the
rapid-cooling.
Apoptosis in umbilical cord blood mononucleated
cells that went through the cryopreservation process
was also evaluated using the Terminal deoxynucleotidyl
transferase-mediated dUTP Nick End Labeling (TUNEL)
assay. The results were then analyzed using a flow cyt-
ometer [25]. An example taken from one of the results
of TUNEL assay is shown in Figure 3. Table 3 clearly
shows that the percentage of cells experiencing apopto-
sis was higher in the samples that were previously cryo-
preserved using the rapid-cooling than in those that
were previously cryopreserved using the slow-cooling
method. According to the calculation using the depen-
dent t-test, the level of confidence for this result was
95%, which means that there were no significant differ-
ences in the mean values of cells experiencing DNA
fragmentation as a sign of apoptosis between both sam-
ple populations, with a p value < 0.001 (p value ≤0.05).
Therefore, the differences in the evaluation of apoptosis
between two sample populations did not have any sig-
nificant statistical value.
The enumeration of CD34
+ cells was carried out using
a flow cytometer. Analysis of the results was based on
the ISHAGE guidelines. The example taken from one of
the results obtained with the flow cytometer (Figure 4).
Table 4 clearly shows that the number of cells expres-
sing CD34
+ was far higher in the sample that was pre-
viously cryopreserved using the slow-cooling method
than in those that were previously cryopreserved using
the rapid-cooling. According to the calculation using the
Wilcoxon signed-rank test, the level of confidence for
these results was 95%, which means that the number of
CD34
+ cells in the samples that were previously cryo-
preserved using the rapid-cooling was significantly lower
than that in those that were previously cryopreserved
using the slow-cooling method, with a p value = 0.001
(p value ≤0.05).
Discussion
It has long been known that the process of cryopreser-
vation and thawing plays an important role in the
decline of viability in cryopreserved cells. Factors that
are suspected of causing such an occurrence are the
type and concentration of the cryoprotectant and the
cooling and warming rate used during cryopreservation
and thawing. Based on those suspected factors, rapid-
Figure 2 The MDA standard curve.T h i sc u r v ew a st h e n
determined by measuring the absorbance of the cell at 586 nm.
Table 2 The evaluation results of malondialdehyde (MDA)
in mononucleated cell populations that were
cryopreserved by using slow-cooling and rapid-cooling
method
Variable Slow-Cooling Rapid-Cooling p value*
)
MDA (in μM)
Mean (SD) 33.25 (10.67) 56.45 (9.68) < 0.001
Median 35.11 57.92
Range 18.96-51.24 39.27-74.48
*: p value was calculated by using dependent t-test
Figure 3 One result of the TUNEL assay on cells that were
previously cryopreserved. The percentage of cells experiencing
DNA fragmentation (M1) was ± 1.15%, while that of cells that did
not experience DNA fragmentation was 98.85%.
Table 3 The percentage of apoptosis in mononucleated
cell populations that were cryopreserved by using slow-
cooling and rapid-cooling method
Variable Slow-Cooling Rapid-Cooling p value*
)
Apoptosis (%)
Mean (SD) 3.80 (3.06) 5.18 (3.55) 0.138
Median 3.29 4.78
Range 0.67-9.67 1.20-14.41
*: p value was calculated by using dependent t-test
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pared to slow-cooling. As stated previously, rapid-cool-
ing was expected to be able to prevent the formation of
intracellular and extracellular ice crystal as well as mini-
mize the risk of cell injury that usually occurs within
the range of critical temperatures.
As shown in Table 1, our results demonstrate that cell
viability after rapid-cooling was significantly higher than
that after slow-cooling. The mean value of cell viability
after slow-cooling was 75.5%, with overall results ran-
ging from 32.7% to 93.8%. On the other hand, the mean
value of cell viability after rapid-cooling was 91.92%,
with overall results ranging from 77.80% to 98.93%. Our
results were similar to those stated in research by Boyse
et al., which also showed an overall value of cell viability
after cryopreservation with the slow-cooling method
ranging from 13.5% to 67.6% [26]. Other results
reported by Bayer et al. clearly demonstrated that the
viability of hematopoietic stem cells after cryopreserva-
tion using the conventional slow-cooling method was
very low, with a mean value of 62% and an overall value
ranging from 51% to 64% [27]. Based on these results,
we concluded that rapid-cooling as a cryopreservation
method would be better at preserving the viability of
umbilical cord blood mononucleated cells. Our conclu-
sion is based on the fact that there was none or less ice
crystal formation in the intracellular extracellular region.
As reported earlier, there were differences in the type
and amount of cryoprotectant used in slow-cooling and
rapid-cooling. The media used in the rapid-cooling
Figure 4 Analysis of CD34
+ enumeration using ISHAGE guidelines. The results of the CD34
+ cell enumeration showed that the number of
CD34+ cells in the samples that were previously cryopreserved by the slow-cooling method is 44.99 cell/μL.
Table 4 The results of the CD34
+ enumeration in mononucleated cell populations that were cryopreserved by using
slow-cooling and rapid-cooling method
Variable Slow-Cooling Rapid-Cooling p value*
)
Number of CD34
+ cells (cell/μL)
Rerata (SD) 23.32 (12.23) 2.47 (3.74) 0.001
Median 22.05 0.90
Rentang 7.62-53.39 0.11-13.95
*: p value was calculated by using Wilcoxon signed-rank test
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(DMSO), ethylen glycol (EG), and sucrose (see supple-
ment). These media were different from those used in
the slow-cooling method, which consisted of only
PBShA, DMSO, and sucrose (see supplement). The
addition of ethylene glycol to the cryopreservation med-
ium used in the rapid-cooling method increased the
viscosity required by the preserved materials to produce
ag l a s s - l i k ea p p e a r a n c eo rv i t r e o u ss t a t e .W ea l s os u s -
pected that rapid-cooling decreased the potential for
injury within the range of critical temperatures. As
reported in Methods section, less time was needed for
temperature changes within the range of critical tem-
peratures than in the slow-cooling method. The shorter
time resulted in a lesser risk of structural lipid changes
that could potentially lead to cell death.
It is noteworthy that our results also showed that the
malondialdehyde level after rapid-cooling was signifi-
cantly higher than that after slow-cooling. Malondialde-
hyde is a substance that has long been known to be a
major end product of lipid peroxidation. As shown in
Table 2, the mean value of malondialdehyde in cells that
were cryopreserved using the rapid-cooling was 56.45
μM, while that of cells that were cryopreserved using
the slow-cooling method was 33.25 μM, both with a p
value of 0.001. The higher value of malondialdehyde
shows that there was more lipid peroxidation, resulting
in the damage of the cell membrane after rapid-cooling.
This result was in obvious contrast to the theory in
which rapid-cooling could prevent or minimize damage
to the cell membrane due to a very rapid cooling time.
Based on the results shown in the evaluation of malon-
dialdehyde, rapid-cooling seems to be a less effective
method for the cryopreservation of umbilical cord blood
mononucleated cells.
When cell viability is compared, the malondialdehyde
value seems highly contradictory. Ideally, less viability
would most probably also occur with a higher malon-
dialdehyde value. We assumedt h a tt h ec o n t r a d i c t o r y
value of malondialdehyde and cell viability might be due
to the fact that lipid peroxidation is not the only cause
of cell death. Many other mechanisms that could lead to
necrosis and apoptosis have the potential to cause a
decrease in cell viability. Another explanation for this
phenomenon is the fact that lipid peroxidation is one of
the earliest events in the process of cell death. There-
fore, a high value of malondialdehyde could also even-
tually result in cell death. In the literature studied, we
f o u n dt h a tt h i sr e s u l tw a ss i m i l a rt ot h o s eo b t a i n e db y
Schuffner et al., in which insignificant changes were
reported in lipid peroxidation in samples that had been
cryopreserved using the slow-cooling method and pre-
viously exposed to a TEST-yolk buffer and glycerol
(TYB-G). Furthermore, it has been reported that the
most significant change that could lead to cell death in
slow-cooling is phosphatidylserine externalization [28].
A ss h o w ni nT a b l e3 ,t h ev a l u eo fa p o p t o s i si na
population that had been cryopreserved by rapid-cool-
ing was higher than in that exposed to slow-cooling. As
reported, the mean percentage of apoptosis in the sam-
ples that were cryopreserved using the rapid-cooling
samples was 5.18%, with the overall value ranging from
1.20% to 14.41%. On the other hand, the mean percen-
tage of apoptosis in samples that were cryopreserved
with the slow-cooling method was 3.80%, with the over-
all value ranging from 0.67% to 9.67%. The p value for
both evaluations was 0.138. Hence, we concluded that
there were no significant differences between the sample
populations. As reported earlier, to evaluate the percen-
tage of cell apoptosis, we used the Terminal deoxynu-
cleotidyl transferase-mediated dUTP Nick End Labeling
(TUNEL) assay. The main principle of this essay is
based on labeling the the nucleic acid terminal end of
the fragmented DNA. DNA fragmentation is a major
cause of apoptosis. Unfortunately, DNA fragmentation
is not the only event that could lead to apoptosis. Simi-
lar results showed by Paasch et al.d e m o n s t r a t e dt h a t
cryopreservation is significantly associated with the acti-
vation of caspase-3, caspase-8, and caspase-9, as well as
the disruption of the mitochondrial membrane poten-
tial, but no significant changes were observed for DNA
fragmentation [29]. In contrast, Baumber et al. reported
that cryopreservation promotes DNA fragmentation
[30]. Based on our results, we concluded that both
slow-cooling and rapid-cooling have the potential to
keep apoptosis at a minimum level in cryopreserved
cells. We assumed that DNA fragmentation was not sig-
nificantly affected by cryopreservation. Therefore,
further study, especially regarding the activation of
some caspases that could lead to apoptosis, is critically
needed.
The most interesting results of our study showed that
the enumeration of CD34
+ cells was much lower in
samples that were cryopreserved by the rapid-cooling
method. As shown in Table 4, the mean enumeration
value for CD34+ cells in samples that were cryopre-
served by slow-cooling was 23.32 cells/μL, with an over-
all enumeration value ranging from 7.62 cells/μLt o
53.39 cells/μL. On the other hand, the mean enumera-
tion value in cells that were cryopreserved by rapid-
cooling was 2.47 cells/μL, with an overall enumeration
value ranging from 0.11 cells/μL to 13.95 cells/μL. The
p value for both enumerations was 0.001. Based on
these results, we concluded that slow-cooling is far bet-
ter for preserving the expression of CD34
+ cells.
The massive loss in CD34
+ cell numbers, especially in
samples that were cryopreserved using the rapid-cooling,
could be due to several factors. The first is the death of
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preserved by rapid-cooling. This possibility is doubtful,
since the cell viability in samples that were cryopreserved
using the rapid-cooling was significantly higher. The sec-
ond possibility is the change in the cell surface molecules
expressed by cells that were once hematopoietic stem
cells. This might have happened because of the differen-
tiation into a more mature type of hematopoietic cell or
dedifferentiation into more immature hematopoietic
stem cells. As reported by Krause et al., CD34
+ could be
used as a single molecular marker of hematopoietic stem
cells. It disappeared after the differentiation process [31].
In another publication, Huss reported that more imma-
ture hematopoietic stem cells were observed as a result
o ft h en e g a t i v ee x p r e s s i o no fC D 3 4
+ on its surface [32].
Until now, no further explanation concerning a process
of cryopreservation that could initiate differentiation
and/or dedifferentiation is available. Therefore, more
study needs to be conducted to define the specific bio-
molecular mechanism that effects the differentiation and
dedifferentiation process. Another possible explanation
for this phenomenon is the damage of the cell surface
marker CD34
+ because of the direct effect of the cryo-
protectant used in rapid-cooling. As reported previously,
slow-cooling uses a less cryoprotectant concentration
than that required for rapid-cooling. This could result in
a decreased risk for extreme dehydration in the cells,
which could have an effect on the protein and lipid stabi-
lity within the membrane. Therefore the protein in the
membrane could prevent any denaturation process. On
the contrary, a much higher cryoprotectant concentration
than that used in the rapid-cooling medium could cause
extreme dehydration, which could obviously lead to pro-
tein denaturation. Even though rapid-cooling requires a
large amount of cryoprotectant, the toxicity is somehow
minimized by the very rapid cooling rate in the cryopre-
servation and thawing process. Unfortunately, the con-
tainer used was a 1.8 mL cryovial. Containers of this size
were chosen because the number of mononucleated cells
in every sample reached 3.6 × 10
7 cells. Initially, cell con-
centration in cryopreservation medium was suggested
not to be over 2 × 10
7 cells/mL. Hence, the most suitable
container to be used was a 1.8 mL cryovial. The oversized
collector might have resulted in unequal contact of the
preserved cells with cold and warm temperatures. This
could have caused some cells in the population to be
affected by critical temperatures for a longer time than
cells that were nearer to the container’s wall. For this rea-
son, we concluded that research to determine which con-
tainers are best for rapid-cooling is urgently needed.
Finally, it is possible that the results of CD34
+ enumera-
tion were simply due to unexplainable and undetected
CD34
+ e x p r e s s i o n .T h e r e f o r e ,w es u g g e s tf u r t h e rs t u d y
on the functional evaluation of umbilical cord blood
mononucleated cell populations after cryopreservation,
especially with the use of the rapid-cooling method.
Conclusions
In summary, rapid-cooling is a potential cryopreserva-
tion method for the preservation of umbilical cord
blood mononucleated cells, although further optimiza-
tion of the number of CD34
+ cells after rapid-cooling is
urgently needed.
Supplement
1a The media used in the rapid-cooling method:
▸ 2% phosphate buffer saline human albumin
(PBShA)
▸ 10% dimethyl sulfoxide (DMSO)
▸ 10% ethylen glycol (EG)
▸ 0.5 M Sukrosa
2a The thawing-media used in the rapid-cooling
method:
▸ 2% PBShA
▸ 0.5 M Sukrosa
1b The media used in the slow-cooling method:
▸ 2% PBShA
▸ 10% DMSO
▸ 0.1 M Sukrosa
2b The thawing-media used in the slow-cooling
method:
▸ 2% PBShA
▸ 0.2 M Sukrosa
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